Although many therapeutics have been deployed to combat hyperglycemia, few of them directly target β-cell pathogenesis besides of GLP-1 analogs, such as liraglutide (Santilli et al., 2017), and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin (Xu et al., 2008). Here, DPP4 is linked to Hyperglycemia.